Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR132 | Q9UNW8 | 7/20 | 0.48 |
| ▸ | CMKLR2 | P46091 | 1/20 | 0.46 |
| ▸ | CMKLR1 | Q99788 | 1/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | MMP8 | P22894 | 1/20 | 0.45 |
| ▸ | MME | P08473 | 2/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | MMP12 | P39900 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ECE1 | P42892 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4198783 | 0.90 | GPR132 (0.52) | GPR132CMKLR2CMKLR1FOLH1MMP9 | |
| SCHEMBL30958913 | 0.88 | BACE1 (0.54) | — | |
| SCHEMBL29930986 | 0.86 | ECE1 (0.51) | GPR132CMKLR2CMKLR1FOLH1MME | |
| SCHEMBL4771133 | 0.86 | MME (0.60) | MME | |
| SCHEMBL29531345 | 0.86 | MME (0.60) | MME | |
| SCHEMBL3968374 | 0.86 | MME (0.60) | MME | |
| SCHEMBL29603169 | 0.84 | NAALAD2 (0.51) | GPR132CMKLR2CMKLR1FOLH1MMP9 | |
| SCHEMBL30685124 | 0.84 | MME (0.50) | GPR132CMKLR2CMKLR1MMP9MMP8 | |
| SCHEMBL30724705 | 0.84 | LMNA (0.43) | GPR132MMP9MMP8RECQLMMP12 | |
| SCHEMBL4436681 | 0.84 | GPR132 (0.51) | GPR132CMKLR2CMKLR1FOLH1MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025243217-A1 | CRYSTAL FORMS OF PEPTIDE MOLECULES | JANSSEN PHARMACEUTICA NV (BE) | 2025-11-27 | — | — | WO | disclosed |
| EP-4622991-A2 | SYNTHESIS OF A CYCLIC PEPTIDE | Janssen Pharmaceutica NV (BE) | 2025-10-01 | — | — | EP | disclosed |
| EP-4547337-A1 | NEW PEPTIDES AS SELECTIVE IL-23 RECEPTOR ANTAGONISTS | Sanofi (FR) | 2025-05-07 | — | — | EP | disclosed |
| WO-2024003313-A9 | NEW PEPTIDES AS SELECTIVE IL-23 RECEPTOR ANTAGONISTS | SANOFI (FR) | 2025-03-20 | — | — | WO | disclosed |
| US-20240218014-A1 | SYNTHESIS OF A CYCLIC PEPTIDE | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-04 | — | — | US | disclosed |
| WO-2024003313-A1 | NEW PEPTIDES AS SELECTIVE IL-23 RECEPTOR ANTAGONISTS | SANOFI (FR) | 2024-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240218014-A1 | SYNTHESIS OF A CYCLIC PEPTIDE | VIP, QPCT, PTMS | GPR132 3753/4885CMKLR2 1101/4885CMKLR1 963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.